Angelini Industries Launches Angelini Ventures With EUR 300M

Angelini Industries, a Rome, Italy-based multi-sector Italian industrial group, announced the launch of Angelini Ventures, a corporate venture capital initiative, with a €300M capital commitment.

Angelini Ventures will build and invest in early-stage companies that develop innovative ideas and solutions in biotechnology, digital health and life sciences.

Led by Paolo Di Giorgio, Chief Executive Officer, Angelini Ventures has already made investments of €60m. The current investment portfolio includes Argobio, a Paris-based biotech venture studio; Angelini Lumira Biosciences Fund, a North American fund that invests in early-stage companies; and Pretzel Therapeutics, a Boston-based mitochondrial therapeutics company.

Led by Sergio Marullo di Condojanni, Chief Executive Officer, Angelini Industries is a multinational group with 5,800 employees, operating in 21 countries and generating annual revenues of €1.7 billion. It operates in the pharmaceutical, consumer goods, industrial technology, perfumes and dermo-cosmetics and wine businesses.

FinSMEs

21/10/2022